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Abstract
Vaccinia virus interferes with early events of the activation pathway of the transcriptional factor
NF-kB by binding to numerous host TIR-domain containing adaptor proteins. We have previ-
ously determined the X-ray structure of the A46 C-terminal domain; however, the structure
and function of the A46 N-terminal domain and its relationship to the C-terminal domain have
remained unclear. Here, we biophysically characterize residues 1–83 of the N-terminal domain
of A46 and present the X-ray structure at 1.55 Å. Crystallographic phases were obtained by a
recently developed ab initio method entitled ARCIMBOLDO_BORGES that employs tertiary
structure libraries extracted from the Protein Data Bank; data analysis revealed an all β-sheet
structure. This is the first such structure solved by this method which should be applicable to
any protein composed entirely of β-sheets. The A46(1–83) structure itself is a β-sandwich con-
taining a co-purified molecule of myristic acid inside a hydrophobic pocket and represents a
previously unknown lipid-binding fold. Mass spectrometry analysis confirmed the presence of
long-chain fatty acids in both N-terminal and full-length A46; mutation of the hydrophobic
pocket reduced the lipid content. Using a combination of high resolution X-ray structures of the
N- and C-terminal domains and SAXS analysis of full-length protein A46(1–240), we present
here a structural model of A46 in a tetrameric assembly. Integrating affinity measurements
and structural data, we propose how A46 simultaneously interferes with several TIR-domain
containing proteins to inhibit NF-κB activation and postulate that A46 employs a bipartite bind-
ing arrangement to sequester the host immune adaptors TRAM and MyD88.
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Author Summary
Viruses possess mechanisms to interfere with the host immune system to enhance their
replication. Vaccinia virus, the viral vaccine used to eradicate smallpox, synthesizes many
such proteins. The vaccinia virus protein A46 is one of a series of proteins preventing
expression of host proteins that induce an anti-viral state. A46 acts early to inhibit anti-
viral state induction by specifically binding to certain host adapter proteins such as
MyD88 and TRAM. Here, we extend our knowledge of the A46 structure by determining
the structure of the protein’s N-terminal domain to be an unusual lipid binding fold. In
addition, the full-length A46 molecule has a novel quaternary structure that can both bind
proteins and lipids, indicating that A46 uses a variety of interactions to sequester host pro-
teins, thus impairing the activation of the anti-viral state and improving the efficiency of
viral replication.
Introduction
Viral infection depends not only on the rate and precision of viral reproduction, but also
requires a simultaneously efficient inhibition of host immune responses. Viruses have evolved
varied strategies to interfere with immune responses of the host, including production of
secreted molecules that mimic innate immune receptors, molecules that trap cytokines as well
as the shut-off of the cellular transcription and translation machinery [1, 2]. Vaccinia virus
(VACV), the virus used to eradicate smallpox, has been extensively studied as a model of
virus-host interaction because of its plethora of anti-immune strategies and its large arsenal of
immunomodulator tools [3]. Further interest in VACV stems from its role as a vaccine vector
against important infectious diseases and its potential role against cancer [4, 5].
Amongst approximately 200 genes in the VACV genome, only half encodes for the viral
replication machinery; many of the remaining gene products have roles as extra- and intracel-
lular modulators of the host immunity [6]. The VACV intracellular immunomodulators form
a family of Bcl-2-like (B-cell lymphoma 2 like) proteins with low sequence identity but high
structural similarity to the eukaryotic Bcl-2 protein family [7]. Eukaryotic Bcl-2 proteins pres-
ent a diverse group of pro- and anti-apoptotic regulators that share α-helical BH domains [3,
8]. To date, 11 Bcl-2-like proteins encoded by VACV have been identified. Those such as A46,
A49, A52, B14, N1, K7 and F1 have an experimentally confirmed Bcl-2 fold [9–16]; others
such as C1, C6, C16/B22 and N2 are predicted to have such a fold [10, 17, 18].
NF-κB is a transcriptional factor that responds to the stimulation of Toll-like-receptors
(TLRs) and Interleukin-like-receptors (IL-1R) by inducing expression of effector molecules. In
the uninfected cell, inactive NF-κB is located in the cytoplasm as a precursor or in a complex
with its inhibitor (IκB). Upon stimulation of TLRs by pathogens, a signaling cascade is initi-
ated through the recruitment of adaptor proteins (e.g. MyD88, MAL/TIRAP, TRIF, TRAM)
by the cytoplasmic domains of TLRs, consequent stepwise activation of IRAK2-IRAK6-IRAK4
kinases followed by activation of TRAF6 ubiquitin ligase and activation of the IKK (IκB
kinase) complex. Finally, the release of the active form of NF-κB results from processing of the
precursors or degradation of IκB. Nuclear migration of the free NF-κB permits expression of a
range of cytokines allowing the development of both innate and adaptive immune responses
[19]. VACV Bcl-2-like immunomodulators disrupt NF-κB activation pathways at different
stages by targeting various components [3, 7]. The A46 protein acts close to the plasma mem-
brane by binding numerous TIR-domain containing adaptor proteins such as MyD88, MAL/
TIRAP, TRAM and TRIF as well as TLR4 to prohibit further signal propagation [20].
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We recently determined the structure of the Bcl-2 domain of A46 comprising residues 87–
229 [9]. However, structural information on the N-terminal domain (residues 1–86), its posi-
tion relative to the Bcl-2-like domain and a plausible function were lacking. Here, we report
the crystal structure of the A46 N-terminal domain comprising residues 1 to 76 and demon-
strate that this domain binds fatty acids. Further, small-angle X-ray scattering (SAXS) was
employed to derive a structural model of full-length of A46(1–240). Using a SAXS-derived
model of A46 together with biochemical data, we postulate a mechanism explaining the bio-
logical function of this unusual VACV immunomodulator protein.
Results
Comparison of the members of VACV Bcl-2-like proteins
Members of the VACV Bcl-2-like family whose structure has been determined mainly
comprise a single Bcl-2-like domain with an N- or a C-terminal extension (ranging from
5 to 80 amino acids) or both (Fig 1A). At present, structural information is only available
for the Bcl-2-like domains and a short unstructured N-terminal region of F1L [21] but not
for the rest of extensions. However, the N-terminal extension of A46 spanning residues
1–80 was predicted by PSIPRED (31) to comprise exclusively β-strands. Previous studies
using limited proteolysis on the full-length A46 protein confirmed the presence of a struc-
tured N-terminal domain in the first 80 residues, suggesting that it would be amenable to
crystallography (Fig 1A) [9].
Expression and characterization of the N-terminal domain of A46
To examine the structure and function of the N-terminal domain of A46, we designed two
constructs for expression in E. coli. Both protein expression constructs contained the first
methionine of the full-length protein and comprised 73 or 83 A46 residues, as constructs with
fewer than 73 residues were either insoluble when His6-tagged or could not be removed from
the MBP expression tag. Both variants contained an additional four amino acids (MAQQ, Fig
1B) to improve solubility as observed with full-length A46 [9]. Thus, both fusion proteins had
the following structure: His6-TRX-TEVsite-MAQQ-A46(1-73/83). The average yield of both
proteins was approximately 2.5 mg highly purified protein per L of bacterial culture. However,
as we only obtained diffraction quality crystals with A46(1–83), we performed all subsequent
work with this variant (Fig 1C).
A46(1–83) selectively binds TIR/MyD88 but not TIR/MAL or TIR/TRAM
binding partners
We first examined the ability of A46(1–83) to bind the TIR domains of its proposed cellular
binding partners such as MyD88 and MAL. Using microscale thermophoresis, we previously
demonstrated that the C-terminal domain of A46 binds in the low micromolar range to these
TIR domains; the KD values were slightly lower than those observed with the full-length pro-
tein (Table 1) [9]. In contrast, the N-terminal A46(1–83) binds to TIR/MyD88 but not to TIR/
MAL. The KD value was 8.8 μM, compared to that of 0.52 μM for A46(1–229). We also exam-
ined the binding of the TIR/TRAM domain, another proposed A46 in vivo binding partner, to
A46 [20, 24]. The interaction of full-length A46 and its C-terminal domain with TIR/TRAM
shows KD values of 2.39 μM and 3.62 μM, respectively. However, under the conditions used,
A46(1–83) did not bind to TIR/TRAM (Table 1).
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A46(1–83) is unable to perform an immunomodulatory function in vivo
Given the binding of A46(1–83) to MyD88, we next examined whether this fragment was suffi-
cient to prevent IL-1β induction of NF-κB-mediated transcription using similar cell-based
assays to those described previously [9]. Plasmid amounts were adjusted so that approximately
the same amounts of each A46 variant were expressed; the total amount of transfected DNA
(500 ng) was kept constant by the addition of empty pCAGGS vector. Unlike full-length A46
and the truncated variant A46(87–229), the N-terminal domain exhibits no appreciable inhibi-
tion of the IL-1β driven induction of NF-κB (Fig 2; see figure legend for statistics). Thus, bind-
ing of A46 residues 1–83 is insufficient to independently fulfil an immunomodulatory role.
Ab initio solution of crystallographic phases
We initiated structural studies of the functional form of the N-terminal domain of A46(1–83)
by setting up crystallization trials with commercial screens. Small single crystals of around
20 μm in size were observed after 1 week of incubation at 22˚C. They failed, however, to grow
larger; nevertheless, several datasets were collected using the beam line for high throughput
macromolecular data-collection MASSIF at ESRF, rendering the highest resolution between
1.8 and 2.3 Å. With no known close homologue in the PDB database, we were unable to solve
the phase problem by molecular replacement. Thus, we labelled the protein with seleno-
methionine; diffraction quality crystals grew in the conditions used for the native protein.
Data sets for SAD were collected using the MASSIF beamline up to 1.55 Å resolution. How-
ever, we were unable to phase the structure using the anomalous signals, most likely because
all three methionines in the protein lie in the very N- and C-termini of the A46(1–83) con-
struct and, consequently, are located in flexible regions. Finally, the phases were obtained by
ARCIMBOLDO_BORGES [25] crystallographic software. The program exploits tertiary struc-
ture libraries extracted from the Protein Data Bank for ab initio phasing. A library of 7650
superimposed polyalanine models, representing 925300 variations on the fold of three
stranded antiparallel β-sheets totalling 20 amino acids, was used as fragment hypotheses. This
Fig 1. The VACV A46 protein constructs and purification of A46(1–83). A, Structural alignment of VACV Bcl-2-like
immunomodulators. The structural alignment was generated using the T-coffee online algorithm [22] with additional manual
correction. Protein Data Bank (PDB) codes are 4LQK, 4M0S (A46, [9, 23]), 2VVW (A52, [10]), 2VVY (B14, [10]), 4D5S (A49, [11]),
3JRV (K7, [14]), 2I39 (N1, [12]), 2VTY, 4D2L (F1, [15, 16]). Bullets indicate the residues forming the hydrophobic core of the Bcl-
2-like domains [7]. Portions of proteins seen in three dimensional protein structures are highlighted in grey, helices in red and β-
strands in cyan. B, Schematic representation of expression constructs for the A46 N-terminal domain. HIS, hexahistidine tag. TRX,
thioredoxin solubilisation tag (green). TEV, TEV protease cleavage site. A46 variants (light blue). C, SDS-PAGE analysis of the
purification of A46(1–83). Lane 1, crude cell extract (T); lane 2, total soluble protein in crude cell extract loaded on to Ni-NTA beads
(S); lane 3, flow-through from Ni-NTA beads (FT); lane 4, eluate from Ni-NTA beads with imidazole (E); lane 5, eluate after
incubation with TEV protease (E+TEV); lane 6, 15 μg of final product from concentrated pooled fraction after SEC. The gel
contained 15% acrylamide; proteins were visualized with Coomassie Brilliant Blue R250. Apparent molecular sizes (in kDa) are
indicated on the left.
doi:10.1371/journal.ppat.1006079.g001
Table 1. Analysis of binding of A46 variants to TIR domains of MyD88, MAL and TRAM (KD, μM).
Quaternary Structure MyD88 MAL TRAM
A46(1–229) tetramer 0.46*, 0.52* 1.44*, 1.56* 2.39 ± 0.16
A46(87–229) dimer 0.89*, 1.24* 2.24*, 2.30* 3.62 ± 0.52
A46(1–83) tetramer 8.80 ± 0.63 N.D. N.D.
The values marked with asterisk (*) were previously reported [9] and are shown here for comparison. The remaining values are presented as an average
from at least three measurements ± standard error of the mean. N.D., not detected.
doi:10.1371/journal.ppat.1006079.t001
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three strands arrangement is most frequently found in β-sheets. Computations were executed
on the Gordon supercomputer at the San Diego Supercomputer Center in California. A partial
solution was obtained upon location with PHASER [26] of 4 models extracted from the unre-
lated PDB structures 2QLG, 2GSK, 2EFU, 4DCB as indicated by SHELXE [27] trace correla-
tion coefficients above 40%. The root mean square deviation (rmsd) of the solving library
models against the final structure was in the range of 0.35 Å (model from 4DCB) and 0.61 Å
(model from 2EFU).
Crystal structure of A46(1–83)
A46(1–83) crystallized with two molecules in the asymmetric unit; electron density for a
bound ligand, later identified as myristic acid, was found inside one of the molecules. The two
A46 molecules comprise two β-sheets arranged head to head as an extended β-sandwich (Fig
3A, Table 2). A tetramer is formed over a crystallographic twofold axis continuing the β-sand-
wich with the second dimer rotated approximately 90˚ relative to the first (S1A and S1B Fig).
The PISA server [28] estimates both association interfaces to be present in solution, burying
1276 and 941 Å2.
The A and B independent subunits show marked differences, with a Cα rmsd of 1.3 Å for
the 45 common β-strand residues (Fig 3B); the tetramer can be described as an A/B/B/A
arrangement. Subunit A has 7 β-strands whereas subunit B presents only 6, lacking the most
C-terminal one (Fig 3A). No electron density is seen for either residues 77–83 in subunit A or
Fig 2. Inhibitory effect of full-length and truncated constructs of A46 on the IL-1β stimulated NK-κB
transcription. HEK293T cells were transfected with the indicated amounts of plasmids. Plasmid amounts
were adjusted so that approximately the same amounts of each A46 variant were expressed. After 40 h of
incubation, cells were stimulated with 0.32 ng/ml of IL-1β and incubated for a further 6 h. NF-κB reporter gene
activity was then measured. Data are expressed as the relative stimulation from a representative experiment
from a minimum of three separate experiments, each performed in triplicate. Error bars represent the
standard deviation from the mean. EV, empty vector.
doi:10.1371/journal.ppat.1006079.g002
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67–83 in subunit B, suggesting that these regions may constitute a flexible linker between N-
and C-terminal domains in the full-length molecule.
A46(1–83) and full-length A46 bind long-chain fatty acids
A striking feature of the external β1-β7 face of the A subunit is a partially hydrophobic tunnel,
spanning the whole subunit A and reaching into subunit B (Fig 4A). A length of 22 Å, an aver-
age radius of 2.5–3 Å and an overall cavity volume of 1150 Å3 (S2 Fig) were calculated with the
software MOLE 2.0 [30, 31]. The tunnel is occupied by an extended well-defined electron den-
sity, reminiscent of a myristic acid molecule (Fig 4A). The omit electron density map for the
ligand is presented in S3 Fig. Mass spectrometry and gas chromatography (GC) analysis of the
lipids extracted from purified protein identified the fatty acids C14:0, C16:0 and C16:1 in com-
plex with A46(1–83) (Fig 4B). Repetition of the experiment with a separate A46(1–83) prepara-
tion revealed the same three fatty acids but in different ratios, indicating that the relative
amounts may be preparation dependent. However, in all preparations so far examined, the
C14:0 fatty acid was highly enriched compared to its overall representation in E.coli cells (Fig
4E).
Further, the lipid extraction and identification by mass spectrometry was also done with
three independently purified samples of the full-length A46 as well as two purified samples
Fig 3. Overall structure of the N-terminal domain of A46. A, Two views of the structure of A46(1–83). The dimer comprises subunit A (7 β-
strands) and subunit B (6 β-strands) with the subunits coloured as rainbows from the N- to the C-termini. Myristic acid co-crystallized as a ligand
inside of the cavity and is depicted as sticks; carbon atoms are blue and oxygen ones are red. B, Superimposition of subunit B on subunit A of
A46(1–83) dimer. Subunit A (in blue) and subunit B (in red) were superimposed in PyMOL. MYR, myristic acid. The amino acids most differing
within subunits are indicated. Panel B is related to panel A by a counter-clockwise rotation of 30˚. Drawings were made using PyMOL [29].
doi:10.1371/journal.ppat.1006079.g003
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Fig 4. Identification of the fatty acids co-purified with A46 constructs. A, Stereo view of myristic acid accommodated in a
hydrophobic cavity of A46(1–83) dimer. 2F0-Fc electron density map of myristic acid contoured at 1σ. Subunit A is blue, subunit B is red.
Myristic acid is depicted as sticks, hydrophobic residues are coloured in the colour of respective subunit. Drawings were made using
PyMOL [29]. B, C, D Total fatty acid content of fatty acids present in the extract from A46(1–83), A46(1–229) or A46(87–229),
respectively. Fatty acids released by base and converted to methyl esters and analysed by GC-MS (see material and methods for
details). The figure shows the TIC chromatogram 31–38 min in which the identified fatty acid methyl ester species are marked. E,
Typical content of fatty acid extract from E.coli DE3 cells grown in LB medium at 25˚C.
doi:10.1371/journal.ppat.1006079.g004
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containing the C-terminal domain of A46 (87–229). For the full-length A46, we also identified
the three co-purified fatty acids, C14:0, C16:0 and C16:1; in contrast, purified A46(87–229)
lacked any complexed lipids (Fig 4C and 4D). Hence, only samples containing the N-terminal
domain of A46, either purified independently or as a part of the full-length protein, are capable
of binding fatty acids.
Subunit B, being partially penetrated by the fatty acid, cannot therefore lodge a second mol-
ecule. The cavity, present in subunit A, is collapsed in subunit B, bringing both β-sheets 3.5Å
nearer (Fig 3B). Tyr37 adopts a dual conformation in the two subunits, suggesting a gate-
keeper role as it folds back in subunit A to make room for the myristic acid (Fig 3B). The side
chain of the preceding His36, pointing to the outside and located in the loop displaying highest
differences between both subunits, also has two conformations. A single loop at each side of
the sandwich joins both sheets, allowing the displayed flexibility. One loop (β1 to β2) is
unchanged; the other (β4 to β5), containing four charged residues DRDK, differs between the
subunits, altering its hydrogen bond pattern (Fig 3B). Together with His36, these electrostatic
interactions may provide a lever for myristic acid binding. The absence of bound fatty acid as
well as the lack of the β7 strand in subunit B results in a quite different interaction interface to
that in subunit A, allowing association of two B subunits, with β1 occupying the position
vacated by β7, and thus the assembly of the symmetric tetramer (S1 Fig).
We examined the lipid-binding properties of A46(1–83) by structure-based site-directed
mutagenesis. We introduced the single mutations F3D, H36L, Y37A, Y37W, I72A into the
expression plasmid for A46(1–83) and successfully expressed and purified protein from all var-
iants. Analysis of their lipid content showed that all variants contained C14:0, C16:0 and C16:1
fatty acids. Furthermore, only the variant Y37A had a wild-type amount of lipids; all of the oth-
ers had less bound lipid than the wild-type, with the variant I72A having the lowest value of
29% (S1 Table). To investigate whether the level of bound lipids influence the function of A46,
the I72A mutant of full-length A46 was examined in a NF-κB transcriptional assay in
TLR4-expressing HEK293 cells. The A46 I72A mutant was reproducibly expressed at higher
levels, both in mammalian cells (Fig 5A) and bacteria. The A46 I72A variant could achieve
similar levels of inhibition of NF-κB mediated signalling as the wild-type (Fig 5B); however,
this level could only be reached when a 2-to-3-fold excess of A46 I72A was expressed com-
pared to the wild-type variant (Fig 5A and 5B). Thus, the lower lipid binding capacity of A46
I72A impairs its ability to inhibit TLR4 signalling.
A46 is a tetramer in solution
In the light of the crystal structure, we analysed the oligomeric state of A46(1–83) using SAXS
(Table 3). The theoretical scattering curve of the A46(1–83) tetramer in crystals presents a
good fit to experimental data with Chi2 (Crysol [32]) of 0.66 (Fig 6A) versus a very poor fit for
the possible dimer found in the asymmetric unit with Crysol Chi2 of 13.52 (Fig 6A).
How are the N-terminal and C-terminal domains of A46 oriented relative to one another?
To address this question, we performed SAXS experiments on full-length A46(1–240) (Fig 6B,
Table 3). The envelope is shown in Fig 6C, together with the fitting of the N- and C-terminal
structures. This arrangement agrees with the tetrameric nature of the A46(1–240) and with
proteinase digestion of the linker leading to the production of two domains with almost all
proteinases tested [9].
Discussion
We have determined the first structure of a structured N-terminal extension of a VACV Bcl-
2-like immunomodulator; additionally, we also show that it is complexed with myristic acid.
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The A46(1–83) domain crystallized, forming regular continuous strands in a simple β-sand-
wich structure with few disordered residues (Fig 3A; S1 Fig). Nevertheless, the solution of the
X-ray structure was complex. Due to the crystals’ small size, automatic beam focussing at the
MASSIF beam line was essential. Additionally, selenium anomalous signals could not be used
because of the position of the methionine residues. Molecular replacement also failed due to
lack of a known protein structure to be used as search model. However, the regular crystal
packing allowed high-resolution data sets to be obtained that were initially processed at 1.55 Å
resolution. This high resolution data, together with the short length of the protein, allowed the
Fig 5. A46 I72A is impaired in the inhibition of TLR4-stimulated NK-κB transcription. A, Expression
levels of the myc and FLAG-tagged A46 wild-type and I72A mutant in HEK293T cells. The cells were
transfected with the indicated amounts of plasmids and the expressed A46 was detected by western blotting
with anti-myc antibodies. U-tubulin was used as a loading control and detected with anti-tubulin antibodies. B,
Dose-dependent inhibition of the TLR4-stimulated NK-κB transcription by either A46 wild-type or I72A mutant.
HEK293-TLR4 cells were transfected with the indicated amounts of plasmids. After 40 h of incubation, cells
were stimulated with 500 ng/mL of LPS and MD2 supernatant and incubated for a further 7 h. NF-κB reporter
gene activity was then measured. Data are expressed as the relative stimulation from a representative
experiment from a minimum of two separate experiments, each performed in triplicate. Error bars represent
the standard deviation from the mean. EV, empty vector.
doi:10.1371/journal.ppat.1006079.g005
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phases to be solved using ab initio methods [25]. In this method, which has been used success-
fully for numerous α-helical structures [34], fragments of known structures are employed as
small search models. In our study, phases could be solved by a protein fragment of three β-
strands that resembles part of the structure of A46(1–83), revealing two molecules in the asym-
metric unit.
Refinement of the structure allowed the determination of electron density for residues 1–76
of subunit A and 1–66 in subunit B. The electron density showed clearly that both subunit A
and subunit B were comprised entirely of β-sheets, confirming previous bioinformatic predic-
tions that the N-terminus of A46 has a β-sheet arrangement. Unexpectedly, in the subunit B,
the C-terminal strand β7 is disordered and not visible in the electron density. We propose that
this difference allows A46(1–83) to form tetramers via the subunit B interfaces whilst interact-
ing with ligands through the subunit A interfaces.
A further wholly unexpected feature of A46(1–83) is a partially hydrophobic cavity
which spans the entire subunit A and part of subunit B. The cavity is open on the side of the
A interface and accommodates long chain fatty acids that were co-purified from the E.coli
cell lysate. In the X-ray structure of A46(1–83), clear electron density for C14:0 myristic
acid was found (Fig 4A), with the hydrophobic tail buried in the cavity whereas the carboxyl
group is open to the solvent. Such an orientation leads us to hypothesize that the cavity
might serve as a specific binding pocket for myristoylated binding partners. To this end,
TRAM is the only binding partner of A46 known to be myristoylated; myristoylation is
indeed essential for its innate immune function, providing correct location of TRAM to the
membranes [35]. Binding of A46 to the myristate of TRAM would prevent the insertion of
TRAM into the membrane and thus circumvent intracellular signalling. An acceptable alter-
native hypothesis would be that the bound fatty acids induce asymmetry of the A46(1–83)
Table 3. SAXS data
A46(1–83) A46(1–240)
DATA COLLECTION PARAMETERS
Instrument BioSAXS BM29, ESRF
Beam geometry (μm) 700 x 700
Wavelength (keV) 12.5
q range (Å-1) 0.04–0.50
Exposure time (sec) 10 frames each 1 second
Concentration range (mg ml -1) 15.50 4.40
Temperature (K) 293
STRUCTURAL PARAMETERS
I(0) (cm-1) from Guinier 14.91 ± 0.02 75.53 ± 0.11
Rg (Å) (from Guiner) 2.61 ± 0.09 4.27 ± 0.08
Volume (Å^3) from Porod 68000 199000
MOLECULAR MASS DETERMINATION
Mr estimate from volume (Da) 38857 113714
Calculated monomeric Mr from the sequence (Da) 10012 28221
SOFTWARE EMPLOYED
Primary data reduction EDNA pipeline [33]
Data processing PRIMUS




Structure of the N-Terminal Domain and of the Full-Length Construct of VACV A46
PLOS Pathogens | DOI:10.1371/journal.ppat.1006079 December 14, 2016 12 / 24
dimer, as they block a polymerization interface equivalent to B/B and prevent binding of a
second fatty acid copy in subunit B. In such manner, using the same primary sequence, a
dimer of heterodimers is formed that allows utilization of different interfaces for distinct
Fig 6. SAXS analysis of the N-terminal domain of A46(1–83) and full-length A46(1–240). A, SAXS analysis of the N-terminal
domain of A46 (1–83). Experimental scattering profile is shown with black dots, theoretical scattering curve of A46(1–83) tetramer
formed by a dimer in the asymmetric unit and its symmetry mate is in red and the one from the asymmetric unit dimer in green. The
graph representing P(r) function with indicated Dmax is in the center and Guinier plot on the right. B, SAXS analysis of the full-length
A46(1–240). Experimental scattering profile is shown with black dots, calculated scattering curves from SAXS models are
presented in blue (ab initio model calculated by DAMMIF) and in green (rigid body modeling by CORAL). The graph representing P
(r) function with indicated Dmax is in the center and Guinier plot on the right. C, Superimposition of the ab initio model envelope
(grey surface) with the rigid-body modeling of the N- and C-terminal domains. The N-terminal domain (1–83) is rendered in yellow
and blue, with one dimer is yellow and the other one is blue. The C-terminal domains (87–229) are rendered in salmon. The flexible
regions are presented as magenta dots and include N-termini of A46(1–83), C-termini of A46(87–229) and the linker between A46
(1–83) and A46(87–229).
doi:10.1371/journal.ppat.1006079.g006
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functions such as tetramerization (interface B with 6 β-strands only) or binding of cellular tar-
gets (interface A with 7 β-strands).
The I72A mutant of A46, which binds lower amounts of fatty acids, indeed showed a
reduced ability to inhibit TLR4-stimulated NF-κB-driven transcription compared to the wild-
type protein (Fig 5B). The inhibitory level of the wild-type A46 was achieved by the I72A
mutant when higher quantities of the mutant protein were expressed. This is not unexpected,
as the C-terminal domain alone (A46(87–229)) can bind TIR/TRAM with KD of 3.6 μM
(Table 1). Presumably, at higher concentrations, the C-terminus of the A46 I72A mutant can
compensate for the loss of binding of the lipid-containing N-terminal domain. Pertinently, we
have shown that the C-terminus of A46 alone is capable of efficiently inhibiting MyD88-me-
diated NF-κB activation when IL-1β stimulation system is used [9]. TLR4-stimulated activa-
tion of the NF-κB transcription factor involves both TRAM and MyD88-dependent cascades
[36]; taken together, our data suggest that the N-terminal domain of A46 may play a more
appreciable role in the inhibition of the TRAM pathway than the MyD88 pathway.
To find similarities of A46(1–83) to other known folds, we searched the PDB database with
PDBeFold [37], using subunit A of A46(1–83) as search query. The highest match corre-
sponded to the nuclear movement protein from E. cuniculi GB-M1 (PDBID 2O30, chain B).
Six secondary structure elements were aligned involving 57 residues at an rmsd of 3.39 Å for
45 Cα; however, the mutual orientation of both sheets is markedly different and the CS domain
seen in NudC does not show oligomerisation. Therefore, we searched for similar local folds of
the same connectivity using the same core of 45 residues with the program BORGES [25]. The
closest match for the strands of ligand bound subunit A was extracted from 2XN2, with 3.09 Å
rmsd, whereas for subunit B, a fold extracted from 2OQE gave 2.42 Å. No instance could be
identified of an equivalent fold showing the same structural change upon ligand binding; nev-
ertheless, a survey of the hits revealed recurring instances of carbohydrate binding proteins,
proteins forming pores and participating in the proper insertion of periplasmic proteins into
membranes. These include proteins such as YidC (PDBID 3BLC), located in the periplasmic
space of E.coli that could, theoretically, bind lipidated proteins. The geometry of the local fold
described by the 6 sheets is also close to a part found in pore-forming hemolysins and leuco-
dines. Indeed, the S-F heterodimer in the latter ones achieves asymmetry through the associa-
tion of two components of very different sequence but very close geometry, with up to one C-
terminal strand present in only one of the copies [38].
The structure of the A46(1–83) protein illuminates the oligomerization state of both the N-
terminal extension and the full-length protein. Previous data had indicated the presence of a
tetramer in solution for the full-length A46 and a dimer for the Bcl-2-like C-terminal domain
[9]. The structure of the N-terminal extension shows a tetramer formed by the association
over a crystallographic twofold axis of the two copies present in the asymmetric unit (S1 Fig),
evaluated to be persistent under physiological conditions. SAXS analysis confirmed that that
A46(1–83) is tetrameric in solution (Fig 6A).
For full-length A46 in solution, structural information on the separated N- and C-terminal
domains allowed interpretation of the envelope generated by SAXS. The full-length molecule
has an elongated shape, with the N- and C- domains linked by a flexible, proteolytically sensi-
tive linker that allows movement of the two domains relative to each other (Fig 6C). Rigid
body fitting of the structures in the envelope of the full-length A46 using CORAL software
[39] indicated a movement of 90 degrees between the two domains.
What are the implications of this structural data for the function of A46 in inhibiting signal-
ling through the TRAM and MyD88 linked pathways? We note that both the N-terminal and
C-terminal domains of A46 can bind the TIR domains of MyD88 (Fig 7A), although the bind-
ing of the N-terminal domain is tenfold lower and the expression of this domain alone does
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Fig 7. Scheme of the postulated interactions of the full-length tetrameric A46 with the TIR domains of MyD88, MAL, TRIF and with full-length
TRAM. The tetramer of A46 is composed of the N-terminal domain (one yellow and one light blue dimer) and C-terminal domain (in salmon). The A subunit
of the N-terminal domain A46(1–76) can either bind MyD88 via protein-protein interactions or use its hydrophobic cavity to accommodate the myristate of
TRAM. The possible array of interactions can include single protein-protein interactions, such as with MyD88, TRAM, MAL or TRIF alone (A), or
simultaneous multiple protein-protein complexes in which some or all TIR adaptor proteins bind to a single tetrameric molecule of A46 (B). TRAM is
presented in red and the myristate, either free or post-translational modification of TRAM, is in grey sticks. TIR/MAL is in purple-grey, TIR/MyD88 is in blue-
purple, TRIF is in green.
doi:10.1371/journal.ppat.1006079.g007
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not inhibit IL-1 induced NF-κB mediated signalling in cells (Table 1, Fig 2). However, we sug-
gest that this bipartite binding enables A46 to generate a chain around the TIR domain of
MyD88 that would prevent the association of its death domain to assemble the Myddosome,
an important structure in the development of the inflammatory response [40]. Additionally,
we propose the binding of the myristate post-translational modification of TRAM by the N-
terminal domain of A46, with the remainder of the TIR domain of TRAM being bound by the
C-terminal Bcl-2 domain of A46 (Fig 7A). For the TIR domain of MAL, an interaction was
only observed with the C-terminal domain of A46; the binding site on A46 for the TIR
domain of TRIF has not yet been determined. We propose here that the interaction is only
with the C-terminal domain (Fig 7A).
The above model assumes binding of only one single TIR domain to the A46 tetramer.
However, as depicted in Fig 7B, each tetramer can theoretically present four binding sites for
TIR domains. We speculate therefore that A46 could form complexes with multiple binding
partners. Indeed, it can even be envisaged that one molecule of A46 could bind one molecule
each of MyD88, MAL, TRAM and TRIF (Fig 7B, right side). Thus, even with low initial con-
centrations of A46, this arrangement would serve to strongly inhibit the inflammatory
response by keeping MyD88 death domains apart, preventing proper cellular localization of
TRAM and sequestering the other signalling and adaptor molecules. Future experimentation
will show the accuracy of these predictions.
Materials and Methods
Plasmids
The cloning of the plasmid containing full-length sequence of the A46R gene from the VACV
Western Reserve strain plasmids (NCBI Gene ID:3707702) as well as of those encoding TIR
domains of mammalian MAL and murine MyD88 was described previously [9]. The N-termi-
nal portion of A46 was amplified from the plasmid containing full-length A46 [9] at different
length using following primers for the indicated fragments: F: 5’-CGCAAGCCATGGCACAG
CAAATGGCGTTTGATATATC-3’ and R: 5’-GCCCGGATCCTTAACT ATACTTATTATA
CAAGTAAGTC-3’ for the fragment A46(1–90); F: 5’-CGCAAGCCA TGGCACAGCAAATG
GCGTTTGATATATC-3’ and R: 5’-GCCCGGATCCTTAAGTCATACTAA CCGGCGTATT
AAC-3’ for the fragment A46(1–83); and F: 5’-CGCAAGCCATGGCACAGCA AATGGCGTT
TGATATATC-3’ and R: 5’-GCCCGGATCCTTAACCAATATTAGTTTCCTCTG-3’ for the
fragment A46(1–73). Obtained fragments were digested with NcoI and BamHI restriction
enzymes and ligated into the pET-TRX1 containing HIS6-TEV-thioredoxin as an expression
tag.
To generate variants of A46(1–83) to examine their lipid-binding properties, we performed
PCR mutagenesis using the pTRX-A46(1–83) plasmid as a template and the following primers:
F3D, F: 5’-GCAAATGG CGGATGATATATCAG -3’ and R: 5’- CTGATATATCAT CCGCC
ATTTGC -3’; H36L F: 5’- GTTAATGATACACTCTACACTGTCG -3’ and R: 5’- CGACAG
TGTAGAGTGTATCATTAAC -3’; Y37A, F: 5’-GATACACACGCCACTGTCGA-3’ and R:
5’-TCGACAGTGGCGTGTGTATC-3’; Y37W, F: 5’-GATACAC ACTGGACTGTCGAATT
TG -3’ and R: 5’-CAAATTCGACAGTCCAGTGTGTATC-3’; I72A, F: 5’- GAAACTAATG
CTGGTTGCGCGG -3’ and R: 5’- CCGCGCAACCAGCATT AGTTTC -3’. The generated
PCR products were digested with DpnI and subsequently transformed in E.coli TOP10 compe-
tent cells.
For expression in mammalian cells, the plasmids coding for the full-length A46 and C-ter-
minal portion of A46 with the respective tags were cloned previously [9]. For the cloning of
the N-terminal domain of A46(1–83), the gene was obtained by amplification from the
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plasmid carrying the full-length A46 with the primers F: 5’-GCCCGAATTCCGAGAATGGA
GCAGAAACTCA TCTCTGAAGAGGATCTGGCGTTTGATATATC-3’ and R1: 5’-CCGC
TCGAGTTACTTA TCGTCGTCATCCTTGTAATCAGTCATACTAACCGGCG-3’ or R2:
5’-CCGCTCGAGTTA AGTCATACTAACCGGCG-3’ to yield myc-A46(1–83)-FLAG or
myc-A46(1–83), respectively. The amplified DNA fragments were digested with XhoI and
EcoRI restriction enzymes and ligated into the pCAGGS vector [41].
The plasmid encoding a GST-fusion of the TIR domain of human TRAM (amino acid resi-
dues 66–235) was a kind gift from Dr. H. Tochio [42].
Expression and purification of full-length A46, TIR/MyD88 and TIR/MAL were per-
formed as described previously [9].
Expression and purification of the N-terminal part of A46
E. coli BL21 (DE3) competent cells were transformed with the plasmids coding for the variants
of the N-terminal domain of A46. The expression was performed in 2 liters of LB medium con-
taining kanamycin (50 mg/liter). The cells were grown at 37˚C until the mid-log phase (A600 =
0.6). Expression was induced with 0.25 mM isopropyl 1-thio-β-D-galactopyranoside at 23˚C.
After 4 hours, cells were harvested and resuspended in 20 mM Tris-HCl, pH 8.5, 100 mM
NaCl, 25 mM imidazole, 5% glycerol and 10 mM β-mercaptoethanol. An EmulsiFlex C3
homogenizer (Avestin) was used for cell lysis. The soluble phase was cleared from insoluble
material by centrifugation at 18000 rpm for 30 min. Recombinant proteins were bound to Ni-
NTA agarose (5 Prime) charged with 300 mM NiCl2 and pre-equilibrated with lysis buffer.
Resin was washed with five column volumes of lysis buffer and proteins of interest were eluted
in three column volumes of 20 mM Tris-HCl, pH 8.5, 300 mM NaCl, 200 mM imidazole and
15 mM β-mercaptoethanol. Recombinant TEV protease was added to release A46 domains by
proteolysis during overnight dialysis against 20 mM Tris-HCl, pH 8.5, 150 mM NaCl, 10 mM
imidazole and 15 mM β-mercaptoethanol. The protein of interest was separated from the pro-
tease and the tag by four passages through Ni-NTA resin pre-equilibrated with the dialysing
buffer. The resulting protein solution was dialysed against 20 mM Tris-HCl, pH 8.5 and 2 mM
DTT for 2 hours. SEC with a HiLoad 16/60 Superdex 75 (GE Healthcare) was performed as
final purification step in 20 mM Tris-HCl, pH 8.5 and 10 mM DTT. The concentration of the
protein of interest was measured by NanoDrop ND-1000 (Thermo Scientific). The accuracy of
NanoDrop measurements was confirmed by additional measurement of the concentration of
two samples from independent purifications using BCA Protein Assay Reducing Agent Com-
patible kit (Thermo Scientific) as described by the manufacturer.
Microscale thermophoresis
Microscale thermophoresis protein-protein interaction studies were performed on the Mono-
lith NT.115 (Nanotemper Technologies, Munich) using fluorescently labeled proteins as
described [43, 44]. For the TIR/MAL, TIR/MyD88 and TIR/TRAM protein labeling, the stan-
dard labeling kit for the fluorescent dye Alexa Fluor 647 from Nanotemper was used. Solutions
of unlabelled A46(1–229), A46(87–229) and A46(1–83) were serially diluted from 150–450 μM
to 8–20 nM in the presence of 30–70 nM of one of the labeled TIR/MAL, TIR/MyD88 or TIR/
TRAM proteins. Measurements were performed at 25˚C in 20 mM TrisHCl pH 8.5, 100 mM
NaCl, 5% glycerol, 1 mM TCEP, 1 mM EDTA, 0.05% Tween 20 using 50% LED power and
60% or 80% IR-laser power. Data analysis was performed with Nanotemper analysis software,
v.1.2.101.
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Protein crystallisation and data collection
Crystals of A46(1–83) and A46(1–73) were initially obtained at protein concentration of 6.75
and 3.5 mg/ml, respectively, in 20 mM TrisHCl pH 8.5 and 10 mM DTT in multiple buffer for-
mulations of the PACT Premier crystallization screen (Molecular Dimensions, Suffolk, UK)
using the sitting-drop vapour diffusion technique and a nanodrop-dispensing robot (Phoenix
RE; Rigaku Europe, Kent, United Kingdom). We obtained crystals of both protein constructs;
however, for A46(1–73) the crystals were not amenable for diffraction experiments. For A46
(1–83), the largest crystals grown in 100 mM HEPES 7.0, 20% PEG6000 and 0.2 M of one of
following salts NaCl, LiCl or NH4Cl were mounted in the loop and flash-cooled in liquid nitro-
gen. Crystals with selenium methionine labeled A46(1–83) were obtained in the same buffer
formulations. The diffraction data set was collected at 100K at the peak of Se at λ = 0.979 Å at
the beamline MASSIF-1 ID30A-1 at the European Synchrotron Radiation Facility (Grenoble,
France) to 1.55 Å resolution and processed using the XDS package [45]. Crystals belonged to
the space group C2 (a = 65.79 Å b = 59.5 Å c = 47.26 Å).
Structure determination and refinement
The structure was solved by ARCIMBOLDO_BORGES ab initio phasing software [25] com-
bining fragment search with Phaser [26] and density modification with SHELXE [46] on the
supercomputer Gordon at the SDSC.
Autobuilding was carried out using the program AutoBuild from the Phenix package [47].
The structure was refined using the program Phenix Refine [48] and manual adjustments with
the software Coot [49]. Stereo-chemistry and structure quality were checked using the pro-
gram MolProbity [50]. Data collection and refinement statistics are reported in Table 2.
Accession code
The coordinates of the A46(1–83) X-ray structure have been deposited in the Protein Data
Bank (PDB) database, accession number 5EZU. The experimental SAXS data and derived
models of the either full-length A46 or its N-terminal domain have been deposited in small
angle scattering biological data bank (SASBDB) with the deposition codes SASDBL7 and
SASDBK7.
SAXS analysis
SAXS experiments for the A46(1–83) and full-length A46(1–229) were performed at 0.9918 Å
wavelength ESRF at BioSAXS beamline BM29 coupled to the Superdex 200 10/300 exclusion
column (Grenoble, France) and equipped with PILATUS 1M detector at 2.867 m distance
from the sample, 0.04< q< 0.5 Å-1 (q = 4π sin θ/λ, 2θ is the scattering angle). The data were
collected using protein concentrations of 15.5 and 4.4 mg/ml for the A46(1–83) and A46(1–
240), respectively. The samples were in a buffer containing 20 mM Tris-HCl pH 8.5, 10mM
DTT and the measurements were performed at 20˚C. The data were processed and analyzed
using the ATSAS program package [51]. The radius of gyration Rg and forward scattering I(0)
were calculated by Guinier approximation. The maximum particle dimension Dmax and P(r)
function were evaluated using the program GNOM [52]. To demonstrate the absence of con-
centration dependent aggregation and interparticle interference in the both SAXS experi-
ments, we inspected Rg over the elution peaks and performed our analysis only on a selection
of frames in which Rg was most stable (S4 Fig). Overall, such stability of Rg over the range of
concentrations observed in the SEC elution indicates that there were no concentration-depen-
dent effects or interparticle interference. The data collection and structural parameter from
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SAXS analysis are summarized in Table 3. The ab initio models were derived using DAMMIF
[53]. 40 individual models were created for each run, which were then overlaid and averaged
using DAMAVER. For the oligomeric state assessment, the theoretical scattering from either
theoretical dimer or tetramer using the high-resolution structure (5EZU) was performed.
First, the residues missing in the crystal structure were added by CORAL modelling; later the
theoretical scattering curves were generated using CRYSOL and compared to the SAXS experi-
mental data for A46(1–83). To obtain a pseudo-atomic model of the full-length A46, CORAL
[39] software was used with the structures for A46(1–83) (5EZU) connected by dummy resi-
due linkers to A46(87–229) (4LQK); the C-terminal domain A46(87–229) was extended by
16–19 dummy residues to imitate the full length of the A46 protein.
Cell culture and reporter gene assays were performed as reported previously [9]. The fol-
lowing expression plasmids were used: the full-length myc-A46(1–240)-FLAG (amounts 200,
150 ng), the N-terminal domain A46(1–83)-FLAG (100, 50 ng), the C-terminal domain A46
(87–229)-FLAG (400, 300 ng). The amount of DNA per well was kept constant at 500 ng by
supplementation with pCAGGS empty vector.
Human embryonic kidney cells 293 stably transfected with TLR4 or MD2 were kind gifts
from Dr. Sylvia Knapp. HEK293-TLR4 and HEK293-MD2 were maintained in DMEM sup-
plemented with 10% fetal calf serum, 1% penicillin/streptomycin and 0.5 mg/ml geniticin
G418. To perform a reporter assay with a wild-type or lipid-binding mutant of A46,
HEK293-TLR4 cells were grown in 24-well plates and transfected with 80 ng pNF-κB-luc
reporter plasmid (Firefly luciferase), 20 ng of pRL-TK (Renilla luciferase) internal control and
300 ng of the respective A46 containing plasmid. The supernatant from HEK293-MD2 cells
was filtered and added in a ratio of 1:4 with DMEM to HEK293-TLR4 in the stimulation assay.
40 hours post transfection, HEK293-TLR4 cells were stimulated by addition of MD-2 superna-
tant, DMEM and 500 ng/ml of LPS. After 7 h, cells were collected, lysed in Passive Lysis Buffer
(Promega) and whole cell lysates were analyzed for luciferase activity using the Dual-Luciferase
Reporter Assay (Promega). Firefly luciferase activity was normalized by Renilla luciferase
activity.
Expression levels of myc-A46-FLAG and myc-A46-FLAG I72A in HEK293T cells were esti-
mated by western blotting. Myc-tagged A46 variants were detected with monoclonal anti-myc
4A6 antibody at a dilution of 1:1000 (Millipore), U-tubulin was used as a loading control and
detected with monoclonal anti-tubulin GTU-88 antibody at a 1:5000 dilution (Sigma).
Analysis of fatty acid content by negative ion ES-MS survey scans
Lipid extractions from purified recombinant proteins were achieved by two different methods.
Method A: 3 successive vigorous extractions with 10 volumes of diethyl ether after treatment
with 2 volumes of 6M HCl overnight. The ether extracts were evaporated under nitrogen and
analysed by electrospray mass spectrometric and tatty acid methyl ester analysis as described
below.
Method B: 3 successive vigorous extractions with ethanol to fully denature proteins (final
90% v/v) [54]. The pooled extracts were dried by nitrogen gas in a glass vial and analysed by
electrospray mass spectrometry.
For electrospray mass spectrometry analysis, extracts were analyzed on a Absceix 4000
QTrap, a triple quadrupole mass spectrometer equipped with a nanoelectrospray source as
described previously [55].
Quantification of the fatty acids from method A were done by conversion to the corre-
sponding fatty acid methyl esters (FAME) followed by GC-MS analysis as described previously
[56] using the following GC temperature program: 70˚C for 12 min followed by a gradient to
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220˚C at 4˚C/min and held at 220˚C for a further 10 min. Mass spectra were acquired from
50–500 amu. The identity of FAMEs was carried out by comparison of the retention time and
fragmentation pattern with mixtures of FAME standards.
Supporting Information
S1 Fig. Tetramer as a functional state of A46(1–83). A, Stereo view of crystal packing of A46
(1–83). The tetramer is composed of two symmetry related dimers, one in yellow and the
other in blue. B, Comparison of A46(1–83 the dimer (A/B) and the tetramer (B/B) interfaces.
Dimers are presented in yellow and blue, residues involved in interface formation are in sticks,
comprising eight salt bridges, 27 H-bonds and numerous hydrophobic bonds (S2 Table). In
the B/B tetrameric interface, the PISA server finds 10 salt bridges, 20 H-bonds and hydropho-
bic bonds (S3 Table). Insets show enlargement of dimer and tetramer interfaces. Drawings
were made using PyMOL [29].
(TIF)
S2 Fig. The tunnel is shown in white on the sagittal cut of the A46(1–83) dimer, rotated to
adjust orientation to that of the graph. The radius values and the length of the tunnel are pre-
sented in the graph. The star indicates the starting point of the tunnel. Measurements and visu-
alization were performed with online software MOLE 2.0 (http://mole.upol.cz/) [30, 31].
(TIF)
S3 Fig. Omit difference electron density map for myristic acid accommodated in the cavity
of A46(1–83) dimer. The map is contoured at 1σ and calculated with coefficients |Fo−Fc|. The
myristate is presented in sticks, where carbon atoms are blue and oxygen ones are red.
(TIF)
S4 Fig. Analysis of Rg over elution peak in SEC-SAXS. The Rg (black curve) and I(0) (red
curve) are plotted versus recorded frames in SEC-SAXS profiles for either A46(1–83) or A46
(1–240) proteins. The frames used for the further analysis and model building are highlighted
in gray. For A46(1–83), frames 354–389 were used; for A46(1–240), frames 479–499 were
used.
(TIF)
S1 Table. Relative quantification of the major fatty acids extracted from A46(1–83) vari-
ants.
(DOCX)
S2 Table. Residues involved in formation of dimeric interfaces.
(DOCX)
S3 Table. Residues involved in formation of tetrameric interfaces.
(DOCX)
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